To investigate bimekizumab efficacy in scalp, nail and palmoplantar psoriasis.In this analysis, data are included from the BE SURE, BE VIVID, BE READY, and BE RADIANT phase 3/3b trials (48-56 weeks) and BE BRIGHT open-label extension (144 weeks). Adults with moderate to severe plaque psoriasis and scalp/palmoplantar Investigator's Global Assessment (IGA) score ≥3 or modified Nail Psoriasis Severity Index (mNAPSI) >10 at baseline were randomized to bimekizumab or comparators (adalimumab, ustekinumab, secukinumab, placebo). Higher rates of complete clearance of scalp and palmoplantar psoriasis were generally observed at Week 4 with bimekizumab than comparators.At Week 24, rates of complete resolution of scalp/nail/palmoplantar psoriasis were 77.7%/39.8%/78.7% with bimekizumab and 58.1%/24.5%/73.3% with adalimumab; at Week 52, 71.9%/54.0%/85.2% with bimekizumab and 51.8%/30.6%/75.0% with ustekinumab; and at Week 48, 80.6%/69.5%/82.4% with bimekizumab and 71.6%/52.5%/76.8% with secukinumab. Complete scalp/nail/palmoplantar clearance rates were sustained through 4 years' bimekizumab treatment (79.5%/61.6%/88.7%). Bimekizumab consistently showed higher rates of complete clearance of psoriasis in high-impact areas along with greater patient-reported health-related quality of life benefits than comparators. Responses were sustained over 4 years, which may lead to improvements in patients' quality of life.
Trial registration
BE SURE (NCT03412747), BE VIVID (NCT03370133), BE RADIANT (NCT03536884), BE READY (NCT03410992), BE BRIGHT (NCT03598790).
